FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992535529> ?p ?o ?g. }

• W1992535529 endingPage "1840" @default.
• W1992535529 startingPage "1831" @default.
• W1992535529 abstract "Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged ≥80 years were at increased risk of early discontinuation. Within 1 year after discontinuation, 24.3 % restarted therapy, yet 47.0 % persisted for 1 year.The risk of osteoporotic fracture can effectively be reduced with use of anti-osteoporosis drugs. However, little is known about persistence with these drugs after fracture where subsequent fracture risk is high. The aims were to determine long-term persistence with anti-osteoporosis drugs among fracture patients, including its determinants, and to describe restart and subsequent persistence.A cohort study was conducted within the Dutch PHARMO Database Network. Patients aged ≥50 years (n = 961) who received anti-osteoporosis drugs within 1 year after fracture, but not in the preceding year, were included (2002-2011). Persistence (defined as the proportion on treatment) and the proportion restarting after discontinuation were estimated using Kaplan-Meier analyses. Time-dependent Cox regression was used to identify determinants of non-persistence including age, sex, initial dosage regime, fracture type, comorbidities, and drug use.Persistence with anti-osteoporosis drugs was 75.0 % (95 % confidence interval (CI) 72.0-77.7) and 45.3 % (95 % CI 40.4-50.0) after 1 and 5 years, respectively. A significant determinant of non-persistence was age ≥80 years (reference 50-59 years: adjusted hazard ratio [adj. HR] 1.65; 95 % CI 1.15-2.38). This effect was not constant over time (≤360 days following initiation: adj. HR 2.07; 95 % CI 1.27-3.37; >360 days: adj. HR 1.08; 95 % CI 0.62-1.88). Within 1 year after discontinuation, 24.3 % (95 % CI 20.1-29.2) restarted therapy, yet 47.0 % persisted for 1 year.This study identified suboptimal persistence with anti-osteoporosis drugs among fracture patients. Major target groups for measures aimed to improve persistence may be those aged >80 years and those restarting therapy." @default.
• W1992535529 created "2016-06-24" @default.
• W1992535529 creator A5034083636 @default.
• W1992535529 creator A5035747289 @default.
• W1992535529 creator A5036526464 @default.
• W1992535529 creator A5049645213 @default.
• W1992535529 creator A5063928355 @default.
• W1992535529 creator A5073590530 @default.
• W1992535529 creator A5076342582 @default.
• W1992535529 creator A5084013498 @default.
• W1992535529 creator A5085427272 @default.
• W1992535529 creator A5088452833 @default.
• W1992535529 date "2015-03-31" @default.
• W1992535529 modified "2023-10-18" @default.
• W1992535529 title "Long-term persistence with anti-osteoporosis drugs after fracture" @default.
• W1992535529 cites W1562584460 @default.
• W1992535529 cites W1601836463 @default.
• W1992535529 cites W1741567663 @default.
• W1992535529 cites W1968343808 @default.
• W1992535529 cites W1976118945 @default.
• W1992535529 cites W1985309337 @default.
• W1992535529 cites W1985327136 @default.
• W1992535529 cites W1991845896 @default.
• W1992535529 cites W2012820371 @default.
• W1992535529 cites W2014297925 @default.
• W1992535529 cites W2026327478 @default.
• W1992535529 cites W2027066203 @default.
• W1992535529 cites W2028457344 @default.
• W1992535529 cites W2034094888 @default.
• W1992535529 cites W2035664155 @default.
• W1992535529 cites W2036181578 @default.
• W1992535529 cites W2036222770 @default.
• W1992535529 cites W2041055356 @default.
• W1992535529 cites W2048205542 @default.
• W1992535529 cites W2051376020 @default.
• W1992535529 cites W2063055176 @default.
• W1992535529 cites W2068947159 @default.
• W1992535529 cites W2074724534 @default.
• W1992535529 cites W2078856412 @default.
• W1992535529 cites W2091246702 @default.
• W1992535529 cites W2096307337 @default.
• W1992535529 cites W2096329415 @default.
• W1992535529 cites W2103185679 @default.
• W1992535529 cites W2104991259 @default.
• W1992535529 cites W2106975935 @default.
• W1992535529 cites W2110022366 @default.
• W1992535529 cites W2118729543 @default.
• W1992535529 cites W2120433336 @default.
• W1992535529 cites W2123049012 @default.
• W1992535529 cites W2129480756 @default.
• W1992535529 cites W2131056136 @default.
• W1992535529 cites W2134227600 @default.
• W1992535529 cites W2136173453 @default.
• W1992535529 cites W2139011815 @default.
• W1992535529 cites W2141180254 @default.
• W1992535529 cites W2143034156 @default.
• W1992535529 cites W2143155280 @default.
• W1992535529 cites W2144178229 @default.
• W1992535529 cites W2148894790 @default.
• W1992535529 cites W2160453672 @default.
• W1992535529 cites W2162321211 @default.
• W1992535529 cites W2164521931 @default.
• W1992535529 cites W4211085092 @default.
• W1992535529 cites W4327849113 @default.
• W1992535529 doi "https://doi.org/10.1007/s00198-015-3084-3" @default.
• W1992535529 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4469296" @default.
• W1992535529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25822104" @default.
• W1992535529 hasPublicationYear "2015" @default.
• W1992535529 type Work @default.
• W1992535529 sameAs 1992535529 @default.
• W1992535529 citedByCount "37" @default.
• W1992535529 countsByYear W19925355292015 @default.
• W1992535529 countsByYear W19925355292016 @default.
• W1992535529 countsByYear W19925355292017 @default.
• W1992535529 countsByYear W19925355292018 @default.
• W1992535529 countsByYear W19925355292019 @default.
• W1992535529 countsByYear W19925355292020 @default.
• W1992535529 countsByYear W19925355292021 @default.
• W1992535529 countsByYear W19925355292022 @default.
• W1992535529 countsByYear W19925355292023 @default.
• W1992535529 crossrefType "journal-article" @default.
• W1992535529 hasAuthorship W1992535529A5034083636 @default.
• W1992535529 hasAuthorship W1992535529A5035747289 @default.
• W1992535529 hasAuthorship W1992535529A5036526464 @default.
• W1992535529 hasAuthorship W1992535529A5049645213 @default.
• W1992535529 hasAuthorship W1992535529A5063928355 @default.
• W1992535529 hasAuthorship W1992535529A5073590530 @default.
• W1992535529 hasAuthorship W1992535529A5076342582 @default.
• W1992535529 hasAuthorship W1992535529A5084013498 @default.
• W1992535529 hasAuthorship W1992535529A5085427272 @default.
• W1992535529 hasAuthorship W1992535529A5088452833 @default.
• W1992535529 hasBestOaLocation W19925355291 @default.
• W1992535529 hasConcept C126322002 @default.
• W1992535529 hasConcept C127413603 @default.
• W1992535529 hasConcept C187212893 @default.
• W1992535529 hasConcept C187320778 @default.
• W1992535529 hasConcept C198451711 @default.
• W1992535529 hasConcept C201903717 @default.

• next